With more and more people signing up for weight loss drugs, the potential side effects are starting to attract attention.

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep medicine.

PharmaZee’s weight loss program has gained significant attention for its use of GLP-1 agonists, such as Semaglutide and Tirzepatide ... the pricing structure, the benefits, and common FAQs.

FROM sulphur burps to diarrhoea, we’re all familiar with the brutal side effects of fat jabs – but have you heard of ‘Ozempic feet’?  Ozempic, a medication originally used by ...

Lilly markets its dual GIP and GLP-1 receptor agonist, tirzepatide, as Mounjaro for T2D and Zepbound for obesity, while Novo Nordisk markets its semaglutide drugs as Ozempic for T2D and Wegovy for ...

Lilly currently sells the medicine tirzepatide as weight-loss drug Zepbound and diabetes treatment Mounjaro, both of which are administered by injection. Novo offers semaglutide injectables of ...

Lilly markets its dual GIP and GLP-1 receptor agonist, tirzepatide, as Mounjaro for T2D and Zepbound for obesity, while Novo Nordisk markets its semaglutide ... price gains of Structure ...

Disparities in prescribing semaglutide and tirzepatide for obesity reveal social factors affecting access and highlight the ...